Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reiners KS et al. - The combination of BV and gemcitabine led to partial or complete remission in 3 of 5 patients. Accordingly, VEGF deprivation by the anti-VEGF antibody BV has antitumor activity in established HL tumors in a preclinical model. BV single agent therapy has biologic effects in HL patients indicating clinical activity. On the basis of these results, a prospective clinical study has been initiated to further investigate the impact of this antiangiogenic approach in HL.

Today in Hematology/Oncology...keeping you current

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09

IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma
International Immunology, 12/03/09

Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address